000			02964nam a22003735i 4500
001			297121
003			MX-SnUAN
005			20160429155404.0
007			cr nn 008mamaa
008			150903s2006 sz | o |||| 0|eng d
020			_a9783764374181 _99783764374181
024	7		_a10.1007/3764374187 _2doi
035			_avtls000362748
039		9	_a201509030401 _bVLOAD _c201404121558 _dVLOAD _c201404091335 _dVLOAD _y201402211057 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC261-271
100	1		_aFurr, Barrington J.A. _eeditor. _9332666
245	1	0	_aAromatase Inhibitors / _cedited by Barrington J.A. Furr.
264		1	_aBasel : _bBirkhäuser Basel, _c2006.
300			_aIx, 182 páginas 30 ilustraciones _brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aMilestones in Drug Therapy MDT
500			_aSpringer eBooks
505	0		_aBackground and development of aromatase inhibitors -- Aromatase inhibitors and models for breast cancer -- Clinical pharmacology of aromatase inhibitors -- Clinical studies with exemestane -- Clinical studies with letrozole -- Clinical studies with anastrozole -- The third-generation aromatase inhibitors: a clinical overview -- Lessons from the ArKO mouse -- Possible additional therapeutic uses of aromatase inhibitors.
520			_aMany breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9783764371999
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/3-7643-7418-7 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c297121 _d297121